{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:17:54Z","timestamp":1648761474271},"reference-count":17,"publisher":"American Society of Consultant Pharmacists","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2004,5,1]]},"DOI":"10.4140\/tcp.n.2004.437","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T02:06:28Z","timestamp":1294884388000},"page":"437-444","source":"Crossref","is-referenced-by-count":1,"title":["Drug Forecast\u2014Solifenacin: An Investigational Anticholinergic for Overactive Bladder"],"prefix":"10.4140","volume":"19","author":[{"given":"David R. P.","family":"Guay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2009,7,9]]},"reference":[{"key":"1","article-title":"Urinary incontinence","volume-title":"harmacotherapy. A Pathophysiologic Approach. 5th ed.","author":"E Rovner","year":"2002"},{"key":"2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.326.7394.841","article-title":"Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review","volume":"326","author":"P Herbison","year":"2003","journal-title":"BMJ"},{"key":"3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00210-002-0554-x","article-title":"M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland","volume":"366","author":"K Ikeda","year":"2002","journal-title":"Arch Pharmacol"},{"key":"4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0306-3623(01)00093-3","article-title":"YM905, a novel M3 antagonist, inhibits Ca<sup>++<\/sup> signaling and c-fos gene expression mediated via muscarinic receptors in human T cells","volume":"35","author":"T Fujii","year":"2000","journal-title":"Gen Pharmacol"},{"key":"5","article-title":"Absolute bioavailability of YM905 in healthy male volunteers: a single dose, randomized, two-period crossover study","author":"M Kuipers","year":"2002"},{"key":"6","article-title":"Co-administration of ketoconazole, a potent CYP 3A4 inhibitor, does not affect safety or tolerability of YM905","author":"N Smith","year":"2002"},{"key":"7","article-title":"10-mg and 20-mg oral doses of YM905, a novel, bladder-selective antimuscarinic: pharmacokinetics, pharmacodynamics, and safety in healthy, elderly men and women","author":"R Smulders","year":"2002"},{"key":"8","article-title":"Pharmacokinetics of YM905, a novel, bladder-selective antimuscarinic, are not adversely affected by food","author":"T Uchida","year":"2002"},{"key":"9","article-title":"Multiple dosing with YM905, a novel, bladder-selective antimuscarinic in healthy men: safety, tolerability, and pharmacokinetics","author":"R Smulders","year":"2002"},{"key":"10","article-title":"A placebo-controlled, dose-rising study in healthy male volunteers to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of YM905","author":"R Smulders","year":"2002"},{"key":"11","article-title":"YM905 is effective and safe as treatment of overactive bladder in women and men: results from a phase II study","author":"N Smith","year":"2002"},{"key":"12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1569-9056(03)80112-4","article-title":"European YM905 Study Group. YM905: results of a randomized, double-blind placebo controlled trial in patients with symptomatic overactive bladder","author":"L Cardozo","year":"2003","journal-title":"Eur Urol"},{"key":"13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.2004.04561.x","article-title":"Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled, phase II, dosefinding study","volume":"93","author":"C Chapple","year":"2004","journal-title":"BJU Int"},{"key":"14","article-title":"A double-blind, randomized, placebo and tolterodine controlled trial with YM905 in symptomatic overactive bladder","volume":"51","author":"C Chapple","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"15","first-page":"534","article-title":"Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder","volume":"22","author":"C Chapple","year":"2003","journal-title":"Neurourol Urodyn"},{"key":"16","article-title":"YM905 10 mg increases the proportion of male and female patients with overactive bladder who become continent","volume":"51","author":"J Kaufman","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"17","article-title":"Treatment of overactive bladder: other drug mechanisms","volume":"55","author":"K-E. Andersson","year":"2000","journal-title":"Urology"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T18:17:23Z","timestamp":1497896243000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2004\/00000019\/00000005\/art00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,1]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5,1]]}},"alternative-id":["Q82546241146174W"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2004.437","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5,1]]}}}